查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830995

色素減退症治療市場

Hypopigmentation Disorder Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

色素減退症治療市場預計將從 2024 年的 47 億美元增加到 2031 年的 67 億美元，2025 年至 2031 年的複合年成長率預計為 5.41%。

市場洞察與分析師觀點：色素減退症可能發展為色素脫失症，其特徵是皮膚色素水平欠佳，這與色素完全喪失導致的脫色症不同。推動色素減退症治療市場成長的關鍵因素包括人們對色素減退症認知的提高、美容治療技術的進步以及老齡化人口的穩定成長。此外，白化病、色素減退後和白斑症等色素減退相關疾病的發生率上升預計將在未來幾年推動色素減退症治療市場的發展。此外，消費者對皮膚健康的投入不斷成長以及對治療方案的認知不斷提高，預計很快就會對該市場產生積極影響。天然和植物成分的出現可能會影響色素減退症治療市場的趨勢，因為這些產品對於滿足全球藥妝需求至關重要。相反，美容治療和手術的高昂成本對市場成長構成了挑戰。

根據美國國家臨床試驗 (NCT) 註冊中心的數據，Incyte 公司於 2020 年 6 月啟動了一項 II 期臨床試驗，以評估魯索利替尼在美國治療白斑症的安全性和有效性。因此，與色素減退症相關的臨床試驗數量的增加是支持市場成長的另一個重要因素。

成長動力與挑戰：色素減退症發生率上升推動市場擴張。白色糠疹、白斑症、白化症和發炎後色素減退是與色素減退症相關的關鍵疾病。白癜風是一種全球公認的疾病。 2023年12月發表在《皮膚病學實用與概念》上的一項研究表明，白斑症是一種常見的皮膚病，男女均可發病，但女性發病率更高，超過60%的患者在30歲之前發病。白斑症發病率和盛行率的上升預計將進一步推動色素減退治療的需求。

扎加齊格大學醫學雜誌 2023 年 3 月的一篇文章指出，色素減退症是兒童常見的一類皮膚病，其盛行率在不同國家有所不同，從 3.6% 到 9.9% 不等。此外，微創手術的興起也極大地促進了色素減退症的普及，因為這些手術需要更短的住院時間，從而減輕了疼痛并減少了併發症。根據美國整形外科醫師協會 (ASPS) 的數據，自 2000 年以來，美國實施的微創美容手術數量增加了近 200%。因此，對微創美容手術日益成長的偏好進一步推動了色素減退症治療市場的成長。然而，白斑症和白化病等疾病的光療法費用高昂，而白斑症手術治療費用昂貴，限制了這些療法的普及，從而限制了色素減退症治療市場的成長。

策略洞察報告細分與範圍：色素減退症治療市場分析透過考察以下細分市場進行：治療類型、疾病指徵和最終用戶。色素減退症治療市場報告的地理範圍包括北美（美國、加拿大和墨西哥）、歐洲（英國、德國、法國、義大利、西班牙和歐洲其他地區）、亞太地區（中國、日本、印度、澳洲、韓國和亞太其他地區）、中東和非洲（阿拉伯聯合大公國、沙烏地阿拉伯、南非和中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲（巴西、阿根廷和南美洲和其他地區中美洲）。

細分分析：基於治療的洞察：依治療類型，市場分為外用藥物、雷射療法、化學換膚、微晶煥膚、光療等。外用藥物在2023年佔據色素減退症治療市場的最大佔有率，預計在2023年至2031年期間將呈現最高的複合年成長率。

基於疾病適應症的洞見：就疾病適應症而言，色素減退症治療市場分為白色糠疹、白化病、白斑症、發炎後色素減退症及其他。白斑症細分市場在2023年佔據了相當大的市場佔有率，預計在2023年至2031年期間將實現最高的複合年成長率。

基於終端用戶的洞察：就終端用戶而言，市場細分為美容診所、皮膚科中心和醫院。美容診所在2023年佔據了色素減退症治療市場的最大佔有率，預計在2023年至2031年的預測期內將實現最高的複合年成長率。

色素減退症治療市場報告範圍區域分析：2023 年，北美佔據色素減退症治療市場的最大佔有率，預計在整個預測期內將保持領先地位。美國主導該地區和全球市場。完善的醫療保健基礎設施、日益​​增強的皮膚健康意識、色素減退相關疾病的患病率上升以及大量為炎症後色素沉著患者提供有吸引力的治療選擇的公司的存在等因素是北美市場成長的主要驅動力。此外，亞洲人日益成長的美容意識和不斷提高的美容標準，加上大量公司進入市場和老牌企業的持續成長，都是亞太地區色素減退症治療市場擴張的重要因素。

競爭格局與重點公司：色素減退症治療市場的預測可以幫助利害關係人制定成長策略。色素減退症治療市場報告中介紹的重點公司包括艾爾建 (Allergan)、修麗可 (SkinCeuticals)、皮爾法伯集團 (Pierre Fabre Group)、因塞特 (Incyte Corporation)、Episciences Inc.、Phio Pharmaceuticals、歐邦琪 (Obagi Cosmeceticals LLC)、Alvo、Abbpora、Abbuora、Abbus LLC。這些公司專注於擴大產品供應，以滿足全球日益成長的消費者需求，並利用其全球影響力服務廣泛的客戶群。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：色素減退症治療市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：色素減退症治療市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：色素減退症治療市場－全球市場分析

  • 色素減退症治療－全球市場概覽
  • 色素減退症治療－全球市場及2031年預測

第7章：色素減退症治療市場－收入分析－依治療類型，2021-2031

  • 概述
  • 外用藥物
  • 雷射治療
  • 化學換膚
  • 微晶煥膚
  • 光療
  • 皮膚移植
  • 色素細胞移植
  • 其他

第 8 章：色素減退症治療市場 - 收入分析 - 按疾病適應症，2021-2031 年

  • 概述
  • 白斑
  • 白化病
  • 色素減退/脫色疤痕
  • 黃褐斑
  • 發炎後色素減退（PIH）
  • 其他

第9章：色素減退症治療市場-收入分析-按最終用戶，2021-2031

  • 概述
  • 醫院
  • 美容診所
  • 皮膚科中心
  • 其他

第 10 章：色素減退症治療市場 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 12 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 13 章：色素減退症治療市場 - 關鍵公司簡介

  • Allergan
  • SkinCeuticals
  • Pierre Fabre
  • Episciences, Inc
  • RXi Pharmaceuticals Corporation
  • Obagi Cosmeceuticals LLC
  • Incyte
  • L’oreal Paris
  • CLINUVEL PHARMACEUTICALS LTD
  • STRATA Skin Sciences
  • TeVido BioDevices, Inc.
  • Courage + Khazaka electronic GmbH
  • AVITA Medical
  • Galderma S.A.
  • Vital Esthetique

第 14 章：附錄

簡介目錄
Product Code: TIPRE00004312

The hypopigmentation disorder treatment market is projected to increase from US$ 4.7 billion in 2024 to US$ 6.7 billion by 2031, with an estimated CAGR of 5.41% from 2025 to 2031.

Market Insights and Analyst View:Hypopigmentation disorders can progress into depigmentation disorders, characterized by suboptimal skin pigment levels, unlike depigmentation conditions which result from the total loss of pigments. Key factors propelling the growth of the hypopigmentation disorder treatment market include heightened awareness of hypopigmentation disorders, advancements in aesthetic treatment technologies, and a steady increase in the aging population. Additionally, the rising incidence of hypopigmentation-related disorders such as albinism, post-hypopigmentation, and vitiligo is expected to drive the market for hypopigmentation disorder treatments in the upcoming years. Furthermore, the growing consumer investment in skin health and awareness of treatment options is anticipated to positively impact this market soon. The emergence of natural and plant-based ingredients is likely to shape trends in the hypopigmentation disorder treatment market, as these products have been essential in fulfilling the global demand for cosmeceuticals. Conversely, the high costs associated with cosmetic treatments and surgeries pose a challenge to market growth.

As per the National Clinical Trials (NCT) registry, Incyte Corporation initiated a phase II clinical trial in June 2020 to assess the safety and efficacy of Ruxolitinib for treating vitiligo in participants in the US. Thus, the increasing number of clinical trials related to hypopigmentation disorders is another significant factor supporting market growth.

Growth Drivers and Challenges:Rising Incidence of Hypopigmentary Disorders Fuels Market Expansion

Pityriasis alba, vitiligo, albinism, and post-inflammatory hypopigmentation are key conditions linked to hypopigmentation disorders. Vitiligo is a widely recognized condition globally. A study published in Dermatology Practical and Conceptual in December 2023 indicates that vitiligo is a common skin condition affecting both genders, though it is more prevalent in females, with over 60% of patients experiencing onset before the age of 30. The increasing incidence and prevalence of vitiligo are expected to further drive the demand for hypopigmentation treatments.

An article in the Zagazig University Medical Journal from March 2023 notes that hypopigmentation disorders are a frequent group of dermatoses in pediatric populations, with prevalence rates varying by country, ranging from 3.6% to 9.9%. Moreover, the rise of minimally invasive procedures, which require shorter hospital stays and result in less pain and fewer complications, has significantly contributed to their growing popularity. According to the American Society of Plastic Surgeons (ASPS), the number of minimally invasive cosmetic procedures performed in the US has increased by nearly 200% since 2000. Thus, the growing preference for minimally invasive cosmetic procedures is further driving the growth of the hypopigmentation disorder treatment market. However, the high costs associated with light therapy for conditions like vitiligo and albinism, as well as the expensive nature of surgical treatments for vitiligo, limit their adoption and consequently restrict the growth of the hypopigmentation disorder treatment market.

Strategic Insights

Report Segmentation and Scope:The analysis of the hypopigmentation disorder treatment market has been conducted by examining the following segments: treatment type, disease indication, and end user. The geographic scope of the hypopigmentation disorder treatment market report includes North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Segmental Analysis:Treatment-Based Insights

By treatment type, the market is divided into topical drugs, laser therapy, chemical peels, microdermabrasion, phototherapy, and others. The topical drugs segment accounted for the largest share of the hypopigmentation disorder treatment market in 2023 and is expected to exhibit the highest CAGR during the period from 2023 to 2031.

Disease Indication-Based Insights

In terms of disease indication, the hypopigmentation disorder treatment market is categorized into pityriasis alba, albinism, vitiligo, post-inflammatory hypopigmentation, and others. The vitiligo segment held a substantial market share in 2023 and is projected to register the highest CAGR from 2023 to 2031.

End User-Based Insights

Regarding end users, the market is segmented into aesthetics clinics, dermatology centers, and hospitals. The aesthetics clinics segment represented the largest share of the hypopigmentation disorder treatment market in 2023 and is anticipated to achieve the highest CAGR during the forecast period from 2023 to 2031.

Hypopigmentation Disorder Treatment Market Report Scope

Regional Analysis:In 2023, North America held the largest share of the hypopigmentation disorder treatment market and is expected to maintain its leading position throughout the forecast period. The US dominates this region and the global market. Factors such as a well-established healthcare infrastructure, increasing awareness about skin health, rising prevalence of hypopigmentation-related diseases, and a significant presence of companies offering appealing treatment options for patients with post-inflammatory hyperpigmentation are key drivers of market growth in North America. Additionally, the growing beauty concerns and rising beauty standards among Asians, along with the influx of companies entering the market and the ongoing growth of established players, are significant contributors to the expansion of the hypopigmentation disorder treatment market in the Asia Pacific region.

Competitive Landscape and Key Companies:The forecast for the hypopigmentation disorder treatment market can assist stakeholders in devising their growth strategies. Key companies profiled in the hypopigmentation disorder treatment market report include Allergan, SkinCeuticals, Pierre Fabre Group, Incyte Corporation, Episciences Inc., Phio Pharmaceuticals, Obagi Cosmeceuticals LLC, Alvogen, Bella Aurora, and AbbVie. These companies are focused on expanding their product offerings to meet the increasing consumer demand globally, leveraging their global presence to serve a wide customer base.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Hypopigmentation Disorder Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Hypopigmentation Disorder Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Hypopigmentation Disorder Treatment Market - Global Market Analysis

  • 6.1 Hypopigmentation Disorder Treatment - Global Market Overview
  • 6.2 Hypopigmentation Disorder Treatment - Global Market and Forecast to 2031

7. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million) - By Treatment, 2021-2031

  • 7.1 Overview
  • 7.2 Topical Drugs
  • 7.3 Laser Therapy
  • 7.4 Chemical Peels
  • 7.5 Microdermabrasion
  • 7.6 Phototherapy
  • 7.7 Skin Grafting
  • 7.8 Pigment cell transplantation
  • 7.9 Others

8. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million) - By Disease Indication, 2021-2031

  • 8.1 Overview
  • 8.2 Vitiligo
  • 8.3 Albinism
  • 8.4 Hypopigmented/depigmented scars
  • 8.5 Melasma
  • 8.6 Post-Inflammatory Hypopigmentation (PIH)
  • 8.7 Others

9. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 9.1 Overview
  • 9.2 Hospitals
  • 9.3 Aesthetic Clinics
  • 9.4 Dermatology Centers
  • 9.5 Others

10. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Hypopigmentation Disorder Treatment Market Overview
    • 10.1.2 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts to 2031
    • 10.1.3 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Treatment
    • 10.1.4 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Disease Indication
    • 10.1.5 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By End User
    • 10.1.6 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Hypopigmentation Disorder Treatment Market
        • 10.1.6.1.1 United States Hypopigmentation Disorder Treatment Market, by Treatment
        • 10.1.6.1.2 United States Hypopigmentation Disorder Treatment Market, by Disease Indication
        • 10.1.6.1.3 United States Hypopigmentation Disorder Treatment Market, by End User
      • 10.1.6.2 Canada Hypopigmentation Disorder Treatment Market
        • 10.1.6.2.1 Canada Hypopigmentation Disorder Treatment Market, by Treatment
        • 10.1.6.2.2 Canada Hypopigmentation Disorder Treatment Market, by Disease Indication
        • 10.1.6.2.3 Canada Hypopigmentation Disorder Treatment Market, by End User
      • 10.1.6.3 Mexico Hypopigmentation Disorder Treatment Market
        • 10.1.6.3.1 Mexico Hypopigmentation Disorder Treatment Market, by Treatment
        • 10.1.6.3.2 Mexico Hypopigmentation Disorder Treatment Market, by Disease Indication
        • 10.1.6.3.3 Mexico Hypopigmentation Disorder Treatment Market, by End User
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Hypopigmentation Disorder Treatment Market - Key Company Profiles

  • 13.1 Allergan
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 SkinCeuticals
  • 13.3 Pierre Fabre
  • 13.4 Episciences, Inc
  • 13.5 RXi Pharmaceuticals Corporation
  • 13.6 Obagi Cosmeceuticals LLC
  • 13.7 Incyte
  • 13.8 L’oreal Paris
  • 13.9 CLINUVEL PHARMACEUTICALS LTD
  • 13.10 STRATA Skin Sciences
  • 13.11 TeVido BioDevices, Inc.
  • 13.12 Courage + Khazaka electronic GmbH
  • 13.13 AVITA Medical
  • 13.14 Galderma S.A.
  • 13.15 Vital Esthetique

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud